BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)

Reuters

Yesterday

Feb 18 (Reuters) - Moleculin Biotech Inc MBRX.O:

MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30)
MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIAL
MOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026
MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGING

Source text: ID:nGNX4DJ9zs

Further company coverage: MBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612449226"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612449226\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612449226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612449226","market":"nz","top_or_hot":-1,"title":"BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> Inc <span>MBRX.O</span>:</p><ul><li><p>MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30)</p></li><li><p>MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIAL</p></li><li><p>MOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026</p></li><li><p>MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGING</p></li></ul><p>Source text: <span>ID:nGNX4DJ9zs</span></p><p>Further company coverage: <span>MBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> Inc <span>MBRX.O</span>:</p><ul><li><p>MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30)</p></li><li><p>MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIAL</p></li><li><p>MOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026</p></li><li><p>MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGING</p></li></ul><p>Source text: <span>ID:nGNX4DJ9zs</span></p><p>Further company coverage: <span>MBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBRX","symbol_name":"Moleculin Biotech, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1DU:1","article_id":"2612449226","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612449226","pubTimestamp":1771424001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)Feb 18 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30)MO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBRX":"Moleculin Biotech, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Moleculin Miracle试验提供了40%的初步盲法CRc率（N=30）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBRX":0.9},"content_text":"BRIEF-Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)Feb 18 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30)MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIALMOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGINGSource text: ID:nGNX4DJ9zsFurther company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}